Prempro Plaintiffs Move to Preclude Defense Experts' Testimony

LITTLE ROCK, Ark. - The first two plaintiffs scheduled for federal Prempro MDL trials have moved to preclude defense experts from testifying that there is no reliable scientific evidence that combination hormone therapy can cause breast cancer. In re: Prempro Products Liability Litigation. Case No. 4:03-cv-1507. MDL No. 1507; Reeves v. Wyeth. No. 4:05-cv-00163; Rush v. Wyeth. No. 4:05-cv-00497 (E.D. Ark.).

Linda Reeves and Helene Rush filed the motion June 16 in the U.S. District Court for the Eastern District of Arkansas, arguing that Wyeth's experts do not rely on studies that address whether combination therapy increases the risk of …